Sirukumab
Lua error in Module:Infobox at line 166: malformed pattern (missing ']').
Sirukumab (INN, USAN) (developmental code name CNTO-136) is a human monoclonal antibody designed for the treatment of rheumatoid arthritis.[1] It acts against the proinflammatory cytokine Interleukin 6 (IL-6).
Sirukumab is currently under development by Johnson & Johnson's subsidiary Centocor and has started clinical trials.[2] and reported some phase II results.[3]
In December 2015 three phase III trials (SIRROUND-D, -H and -T) were collecting data.[4]
The drug is currently in phase II clinical trials for the treatment of depression.[1]
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references> tag; parameter "group" is allowed only.
<references />, or <references group="..." /><templatestyles src="Asbox/styles.css"></templatestyles>
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ A Study of the Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy, clinicaltrials.gov
- ↑ Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
- ↑ Glaxo says top-line results positive in late-stage study of sirukumab in rheumatoid arthritis. Dec 2015
- Pages with reference errors
- Drugs that are a monoclonal antibody
- Articles without EBI source
- Chemicals that do not have a ChemSpider ID assigned
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Antidepressants
- Janssen Biotech
- Monoclonal antibody stubs
- Antineoplastic and immunomodulating drug stubs
